Immunocore (ADR)
Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.
$36.62
After-hours close−0.01 (−0.03%)
At close$36.63(−0.33%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.16 | — | — |
| Aug 2026 | −$0.01 | −$0.02 | −100.0% |
| May 2026 | −$0.26 | $0.25 | +196.2% |
| Feb 2026 | −$0.28 | −$0.60 | −114.3% |
| Nov 2025 | −$0.30 | $0.02 | +105.2% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Jan 2021 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.16 | — | — | $152.6M | — | — |
| Aug 6, 2026 | −$0.01 | −$0.02 | −100.0% | $148.8M | $115.9M | −22.1% |
| May 6, 2026 | −$0.26 | $0.25 | +196.2% | $145.4M | $145.0M | −0.3% |
| Feb 25, 2026 | −$0.28 | −$0.60 | −114.3% | $144.5M | $140.1M | −3.1% |
| Nov 6, 2025 | −$0.30 | $0.02 | +105.2% | $142.2M | $103.7M | −27.1% |
The latest year is open to everyone — the 23 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 7, 2025 | ||||||
| Feb 26, 2025 | ||||||
| Nov 6, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 8, 2024 | ||||||
| Feb 28, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 10, 2023 | ||||||
| Mar 1, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 10, 2022 | ||||||
| May 11, 2022 | ||||||
| Mar 3, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 11, 2021 | ||||||
| May 12, 2021 | ||||||
| Mar 25, 2021 | ||||||
| Jan 15, 2021 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||
| Dec 31, 2019 | ||||||